HCPCS Level II code J9312 denotes a 10 mg unit of rituximab administered by injection or infusion. Rituximab is a monoclonal antibody widely used in oncology and certain autoimmune disorders; billing for this drug is important for cost accounting, medication utilization tracking, and reimbursement workflows across outpatient and infusion settings. Nationally, accurate coding of drug units affects drug pass-through payments, outpatient prospective payment calculations, and coverage determinations.

Key payers examined include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical role and service settings, typical payer coverage considerations, and the types of benchmarks and policy updates that affect utilization and payment for injectable oncology biologics. The publication summarizes how J9312 is used on service lines, common billing modifiers associated with injectable drugs, and where to look for payer-specific guidance.

This analysis is written for a national audience and focuses on operational and policy-relevant facts: what the code represents, the settings where it is typically billed, payer coverage landscape, and the categories of documentation and billing practice that influence reimbursement and compliance.